Results 321 to 330 of about 264,642 (338)
Hypoxia upregulates the expression of PD-L1 via NPM1 in breast cancer. [PDF]
J Immunother CancerYu Y +12 more
europepmc +1 more source
Clinical Interchangeability of PD-L1 Immunohistochemistry Assays in First-Line Non-Small Cell Lung Cancer Management With Cemiplimab. [PDF]
JCO Precis OncolPerez J +15 more
europepmc +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Nature Cell Biology, 2020
PD-L1 has been extensively described as the membrane-bound ligand of PD-1. A recent study discovered a previously unknown role for PD-L1, which is able to bind DNA and thus govern different pathways linked to either evasion of immune surveillance or tumour microenvironment inflammation.
Ping-Chih Ho +2 more
openaire +3 more sources
PD-L1 has been extensively described as the membrane-bound ligand of PD-1. A recent study discovered a previously unknown role for PD-L1, which is able to bind DNA and thus govern different pathways linked to either evasion of immune surveillance or tumour microenvironment inflammation.
Ping-Chih Ho +2 more
openaire +3 more sources
PD1 and PD-L1 Inhibitors for the Treatment of Kidney Cancer: The Role of PD-L1 Assay
Current Drug Targets, 2020Background: Immune checkpoint inhibitors targeting the programmed death receptor ligand 1 (PD-L1)/programmed death receptor 1 (PD-1) pathway represent a drastic change in the treatment landscape of RCC resulting in a dynamic and evolving scenario.
Cimadamore A. +7 more
openaire +3 more sources
American Journal of Surgical Pathology, 2021
Immunotherapy for the treatment of programmed death-ligand 1 (PD-L1) positive locally advanced or metastatic triple negative breast cancer may benefit patients with metaplastic breast cancer (MpBC). Previous study of PD-L1 in MpBC scored tumor cells (TCs), different from Food and Drug Administration-approved scoring methods.
Jorge S. Reis-Filho +13 more
openaire +2 more sources
Immunotherapy for the treatment of programmed death-ligand 1 (PD-L1) positive locally advanced or metastatic triple negative breast cancer may benefit patients with metaplastic breast cancer (MpBC). Previous study of PD-L1 in MpBC scored tumor cells (TCs), different from Food and Drug Administration-approved scoring methods.
Jorge S. Reis-Filho +13 more
openaire +2 more sources
Cancer Immunology, Immunotherapy, 2016
Recently, there has been an increased focus on the immune checkpoint protein PD-1 and its ligand PD-L1 due to the discovery that blocking the PD-1/PD-L1 pathway with monoclonal antibodies elicits striking clinical results in many different malignancies.
Troels Holz Borch +4 more
openaire +4 more sources
Recently, there has been an increased focus on the immune checkpoint protein PD-1 and its ligand PD-L1 due to the discovery that blocking the PD-1/PD-L1 pathway with monoclonal antibodies elicits striking clinical results in many different malignancies.
Troels Holz Borch +4 more
openaire +4 more sources
PD-L1 expression in sebaceous carcinomas
Cancer Immunology, Immunotherapy, 2021Traditional systemic treatments for unresectable, recurrent, and/or advanced sebaceous carcinoma (SC) are ineffective. Tumoral immune microenvironment characterization is essential for considering immune checkpoint inhibitors as a treatment option.A total of 173 resected SCs were reviewed. Clinical information, lesion size, and location were collected.
Maelle Saliba +8 more
openaire +2 more sources
Journal of Cancer Research and Clinical Oncology, 2019
To investigate the associations between programmed cell death ligand-1 (PD-L1) on tumor cells (TCs) or PD-L1 on tumor-infiltrating immune cells (TIICs) and the microsatellite instability (MSI) status in colorectal cancer (CRC).In total, 238 CRC patients were enrolled.
Shung Haur Yang +10 more
openaire +3 more sources
To investigate the associations between programmed cell death ligand-1 (PD-L1) on tumor cells (TCs) or PD-L1 on tumor-infiltrating immune cells (TIICs) and the microsatellite instability (MSI) status in colorectal cancer (CRC).In total, 238 CRC patients were enrolled.
Shung Haur Yang +10 more
openaire +3 more sources